Antithrombotic Treatment for Chronic Coronary Syndrome: Evidence and Future Perspectives.

Autor:	Kulasingam A; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark., Pareek M; Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark., Gragnano F; Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, Caserta, Italy.; Division of Cardiology, A.O.R.N. Sant'Anna e San Sebastiano, Caserta, Italy., Würtz M; Department of Cardiology, Regional Hospital Gødstrup, Herning, Denmark., Pryds K; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark., Calabrò P; Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, Caserta, Italy.; Division of Cardiology, A.O.R.N. Sant'Anna e San Sebastiano, Caserta, Italy., Grove EL; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Jazyk:	angličtina
Zdroj:	Cardiology [Cardiology] 2024; Vol. 149 (5), pp. 502-512. Date of Electronic Publication: 2024 Feb 14.
DOI:	10.1159/000537706
Abstrakt:	Background: The clinical presentation of coronary artery disease can range from asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute coronary syndrome. Chronic coronary syndrome is a frequent condition, and secondary prevention of ischaemic events is essential. Summary: Antithrombotic therapy is a key component of secondary prevention strategies, and it may vary in type and intensity depending on patient characteristics, comorbidities, and revascularisation modalities. Dual antiplatelet therapy is the default strategy in patients with chronic coronary syndrome and recent coronary stent implantation, while antiplatelet monotherapy is commonly prescribed for long-term prevention of cardiovascular events. Oral anticoagulation, in combination with antiplatelet therapy or alone, is used in patients with, e.g., concomitant atrial fibrillation or venous thromboembolism. Key Messages: This review provides an overview of antithrombotic treatment strategies in patients with chronic coronary syndrome. Key messages from current guidelines are conveyed, and we provide future perspectives on long-term antithrombotic strategies. (© 2024 S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu